elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Bladder cancer
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Bladder cancer
RIS
0.003
(Research Intensity Score)
Papers
366
Top papers
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
2024 · 350 citations
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines
2025 · 191 citations
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update
2023 · 510 citations
Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer
2024 · 213 citations
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 · 2159 citations
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
2025 · 76 citations
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
2026 · 58 citations
Treatment of muscle‐invasive and advanced bladder cancer in 2020
2020 · 1143 citations
NAT10 Drives Cisplatin Chemoresistance by Enhancing ac4C-Associated DNA Repair in Bladder Cancer
2023 · 200 citations
Newest papers
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
2026 · 58 citations
Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.
2026 · 12 citations
Lactylation enhances YTHDF3 stability to promote cisplatin resistance via m6A-dependent KDM6B decay in bladder cancer
2026 · 6 citations
Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer
2026 · 4 citations
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
2026 · 1 citations
Delactylation of the tumor suppressor ARHGDIB drives metastasis and chemoresistance in bladder cancer
2026 · 3 citations
TMEM11 promotes cisplatin resistance by inhibiting BNIP3-mediated mitophagy in bladder cancer
2026 · 3 citations
Single-cell insights into cisplatin resistance mechanisms in bladder cancer tumor microenvironment
2026 · 2 citations
Tumor Mutational Burden and Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients Treated with Neoadjuvant Chemotherapy
2026
Browse all papers →
Bladder cancer's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Bladder cancer's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link